Journal
CURRENT OPINION IN BIOTECHNOLOGY
Volume 13, Issue 6, Pages 603-608Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S0958-1669(02)00352-X
Keywords
-
Ask authors/readers for more resources
The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available